Brokers Offer Predictions for VolitionRx FY2024 Earnings

VolitionRx Limited (NYSE:VNRX) – Equities research analysts at Zacks Small Cap increased their FY2024 EPS estimates for VolitionRx in a research report issued on Wednesday, December 4th. Zacks Small Cap analyst S. Ralston now expects that the company will earn ($0.28) per share for the year, up from their prior estimate of ($0.29). The consensus estimate for VolitionRx’s current full-year earnings is ($0.31) per share. Zacks Small Cap also issued estimates for VolitionRx’s Q4 2024 earnings at ($0.06) EPS.

A number of other brokerages have also issued reports on VNRX. Benchmark reiterated a “hold” rating on shares of VolitionRx in a research report on Friday, November 22nd. StockNews.com began coverage on shares of VolitionRx in a report on Friday, December 6th. They issued a “sell” rating on the stock. Finally, D. Boral Capital restated a “buy” rating and issued a $5.00 price objective on shares of VolitionRx in a report on Tuesday.

VolitionRx Trading Down 2.6 %

Shares of VNRX stock opened at $0.57 on Monday. VolitionRx has a 1 year low of $0.43 and a 1 year high of $1.23. The firm’s 50 day moving average is $0.69 and its 200-day moving average is $0.67. The firm has a market capitalization of $53.28 million, a price-to-earnings ratio of -1.60 and a beta of 1.17.

Insider Activity at VolitionRx

In other news, CEO Cameron John Reynolds purchased 139,811 shares of the firm’s stock in a transaction dated Monday, December 9th. The stock was bought at an average price of $0.57 per share, with a total value of $79,692.27. Following the acquisition, the chief executive officer now directly owns 2,117,404 shares of the company’s stock, valued at approximately $1,206,920.28. This represents a 7.07 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Guy Archibald Innes purchased 174,764 shares of the firm’s stock in a transaction dated Monday, December 9th. The stock was purchased at an average cost of $0.57 per share, with a total value of $99,615.48. Following the acquisition, the director now directly owns 617,085 shares in the company, valued at $351,738.45. This trade represents a 39.51 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired 358,266 shares of company stock worth $204,212 over the last ninety days. Company insiders own 12.80% of the company’s stock.

Hedge Funds Weigh In On VolitionRx

A hedge fund recently raised its stake in VolitionRx stock. Ground Swell Capital LLC boosted its stake in VolitionRx Limited (NYSE:VNRX) by 78.8% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 45,959 shares of the company’s stock after acquiring an additional 20,249 shares during the quarter. Ground Swell Capital LLC’s holdings in VolitionRx were worth $28,000 as of its most recent SEC filing. Institutional investors and hedge funds own 8.09% of the company’s stock.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.